Company History
2006
Founded on 14th of November by Roger Nitsch, Christoph Hock and Jan Grimm as a University of Zurich spin-off company after encouragement and advice by serial biotech entrepreneur Karsten Henco (Qiagen, Evotec, Coley, U3)
2007
Seed investment by Karsten Henco
Initiation of Aducanumab/BIIB037 collaboration with Biogen
2008
Labs moved from University to Bio-Technopark Zurich-Schlieren
Initiation of alpha-synuclein, tau and TDP43 programs
2009
In vivo proof-of-concept data with alpha-synuclein antibody
First SOD1 and IAPP antibodies cloned
2010
Alpha-synuclein (Cinpanemab / BIIB054), tau (BIIB076) and TDP-43 programs acquired by Biogen
2011
Aducanumab/BIIB037 in phase 1 clinical development
2012
Aducanumab in phase 1b clinical development
2013
Initiation of ATTR program
2014
Interim read-out shows that aducanumab reduces beta-amyloid in patients with Alzheimer’s disease
2015
First clinical data on aducanumab presented at AD/PD in Nice, France
Aducanumab in phase 3 clinical development
Cinpanemab in phase 1 clinical development
2016
Aducanumab results published in Nature
AL-S Pharma founded to develop AP-101 together with TVM Capital and Lilly’s Chorus unit
Neurimmune collaborates with Biogen on C9orf72 targeted treatments for ALS
2017
BIIB076 in phase 1 clinical development
$200 mio non-dilutive growth financing raised to execute on growth strategy
Collaboration with Ono Pharmaceutical initiated
2018
Cinpanemab in phase 2 clinical development
SOD1 work published in Science Translational Medicine
NSC Therapeutics formed to develop small molecule NSC001 for DLB & AD
2019
Strategic partnership with Novago Therapeutics initiated
NSC001 in phase 1 clinical development
Collaboration with Regenxbio to develop vectorized human antibodies initiated
AP-101 in phase 1 clinical development
Aducanumab showed clinical benefit in Phase 3
2020
NI006 in phase 1 clinical development
RTM technology applied to discover anti-SARS-CoV-2 antibodies
Collaboration with Ethris initiated to develop inhaled mRNA-based antibody therapy for Covid-19
U.S. FDA accepts Biogen's aducanumab Biologics License Application with priority review
EMA accepts Biogen's aducanumab Marketing Authorization Application for Alzheimer's disease
Biogen files Japanese New Drug Application for aducanumab
2021
FDA approval of aducanumab for the treatment of Alzheimer's disease
AP-101 in Phase 2 clinical development
New biomarker data showed that aducanumab reduced plasma-p-tau181
2022
Neurimmune entered into a collaboration with AZ to develop and commercialize NI006
Drug discovery collaboration with Ono expanded
2021
FDA approval of aducanumab for the treatment of Alzheimer's disease
AP-101 in Phase 2 clinical development
New biomarker data showed that aducanumab reduced plasma-p-tau181
2022
Neurimmune entered into a collaboration with AZ to develop and commercialize NI006
Drug discovery collaboration with Ono expanded
2023
Phase 1 POC results for antibody NI006/ALXN2220 published in NEJM
Depletion of IAPP oligomers protects beta cell health in preclinical models
2024
Regained global rights to brain amyloid depleter NI101
ALXN2220/NI006 in Phase 3 clinical development
Long-term safety and efficacy of ALXN2220 presented at ESC Congress
FDA Fast Track Designation for ALXN2220 for depletion of Cardiac ATTR
